Abstract：Objective: To investigate the clinical efficacy of budesonide aerosol inhalation and influence on serum inflammatory factor levels in children with mycoplasma pneumonia. Methods: Totally 100 eligible children were selected and randomly divided into observation group and control group according to the admission numbers, with 50 children in each group. Both groups were given conventional therapies, while the observation group used budesonide spray inhalation additionally. The changes in clinical symptoms and physical signs of the children were observed in the treatment period, and the serum levels of interferon-γ (IFN-γ), tumor necrosis factor -α (TNF-α), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-13 (IL-13) were determined before treatment and after 7 d of treatment, respectively. Results: For the observation group, 32 children were cured, 14 children were responsive to the therapy excellently, 3 children were improved, and 1 child was unresponsive to the therapy; while for the control group, 25 children were cured, 11 children were responsive to the therapy excellently, 9 children were improved, and 5 children were unresponsive to the therapy; and the differences were statistically significant (P<0.05). The observation group had significantly shorter times to disappearances of fever, cough, asthma, and rales in lungs than the control group (P<0.05). Before treatment, the two groups had insignificantly different serum levels of proinflammatory factors such as IFN-γ, TNF-α, and IL-6 (P >0.05); after 7 d of treatment, both groups had significantly decreased serum levels of IFN-γ, TNF-α, and IL-6 compared with those before treatment, but the observation group had significantly greater decreasing extents than the control group (P<0.05). Before treatment, the two groups had insignificantly different serum levels of antiinflammatory factors such as IL-2, IL-10, and IL-13 (P >0.05); after 7 d of treatment, both groups had significantly increased serum level of IL-2 and significantly decreased serum levels of IL-10 and IL-13 compared with those before treatment, but the observation group had significantly greater improving extents than the control group (P<0.05). Conclusion: Budesonide aerosol inhalation can rapidly relieve the clinical symptoms and physical signs, promote normalization of serum levels of antiinflammatory and proinflammatory factors, and elevate the clinical efficacy in children with mycoplasma pneumonia.
李吉红, 张红. 布地奈德雾化吸入对支原体肺炎患儿临床疗效及血清炎性因子水平的影响[J]. 河北医学, 2017, 23(1): 105-107.
LI Jihong, et al. Clinical Efficacy of Budesonide Aerosol Inhalation and Influence on Serum Inflammatory Factor Levels in Children with Mycoplasma Pneumonia. HeBei Med, 2017, 23(1): 105-107.
2017, Vol. 23 
冀公网安备13080202000677号